Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Journal of Cardiovascular Development and Disease · 17.11.2026 · 13 (11) · 606
DOI: 10.3390/jcdd13110606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 17.11.2026. Verfasst von Jiaqi Shen und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Research Plan of SHDC, Hongkou District Health Commission Medical Research Project, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Background
Menstrual changes during antithrombotic therapy for cardiovascular disease remain incompletely characterized.
Methods
In a prospective observational cohort, we compared enrollment and follow-up menstrual assessments from 50 menstruating women treated for cardiovascular indications, including atrial fibrillation/flutter and coronary disease. We assessed within-person changes in menstrual-cycle classification and bleeding duration, together with bleeding-related documentation, healthcare visits, and absences.
Results
The proportion with an abnormal cycle classification increased by 12.0 percentage points (95% CI, 2.0–22.6; 50 pairs), and the proportion reporting menses lasting at least 8 days increased by 12.5 percentage points (95% CI, 2.1–24.8; 48 pairs). For each outcome, six women newly met the definition and none ceased to meet it (exact McNemar p = 0.031). A documentation-based bleeding indicator was present in 17 of 46 evaluable women (37.0%). Menstrual-related healthcare visits and absences were reported by 13 and 6 women, respectively. Comparisons across treatment groups were exploratory because groups were small and differed by cardiovascular indication.
Conclusions
Menstrual changes and related healthcare use and absences were observed during cardiovascular antithrombotic care. Routine assessment of menstrual symptoms may help identify women who need further evaluation and support.
Förderung
- Clinical Research Plan of SHDC
- Hongkou District Health Commission Medical Research Project
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Shen, J., Zhong, Z., Wu, X., Fang, T., Zheng, L., Kang, M., Zhu, Y., Zhang, Y., Wei, Y., Chen, S., Liu, S., Zhang, Q., & Zhou, G. (2026). Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study. Journal of Cardiovascular Development and Disease, 13(11), 606. https://doi.org/10.3390/jcdd13110606
Vancouver
Shen J, Zhong Z, Wu X, Fang T, Zheng L, Kang M, et al. Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study. Journal of Cardiovascular Development and Disease. 2026;13(11):606. doi:10.3390/jcdd13110606
BibTeX
@article{Shen2026,
author = {Shen, Jiaqi and Zhong, Zikan and Wu, Xiaoyu and Fang, Tingting and Zheng, Linqun and Kang, Mei and Zhu, Yan and Zhang, Yu’e and Wei, Yong and Chen, Songwen and Liu, Shaowen and Zhang, Qitong and Zhou, Genqing},
title = {Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study},
journal = {Journal of Cardiovascular Development and Disease},
year = {2026},
volume = {13},
number = {11},
pages = {606},
doi = {10.3390/jcdd13110606}
}
EUVIMED